open access

Vol 67, No 9 (2009)
Other
Published online: 2009-10-12
Submitted: 2012-12-28
Get Citation

Original article
Is Hsp27 a marker of myocardial ischaemia?

Grażyna Józefowicz-Okonkwo, Karina Wierzbowska-Drabik, Marek Kasielski, Ewa Trzos, Anna Gorąca, Jarosław Kasprzak, Maria Krzemińska-Pakuła
Kardiol Pol 2009;67(9):947-952.

open access

Vol 67, No 9 (2009)
Other
Published online: 2009-10-12
Submitted: 2012-12-28

Abstract

Background: Heat shock protein (Hsp) 27 expression in cardiomyocytes increases in response to ischaemia. The extracellular release of Hsp27 from cardiomyocytes is proportional to its intracellular levels.
Aim: To assess the influence of significant coronary artery disease (CAD), which by definition results in chronic myocardial ischaemia, on blood serum levels of Hsp27.
Methods: Blood serum levels of Hsp27 in 62 patients with at least 50% lumen diameter narrowing in at least one main epicardial coronary artery on angiography and in 21 controls with normal coronaries were measured.
Results: Patients with CAD tended to have higher serum level of Hsp27 than controls [0.463 (0.158-0.809) vs. 0.184 (0.099-0.337) ng/ml, p = 0.084]. Serum Hsp27 level in patients with CAD affecting more than a single vessel was significantly increased [0.529 (0.192-1.004) ng/ml] compared with controls (p = 0.035) and with one artery narrowed [0.276 (0.087-0.549) ng/ml, p = 0.041]. No correlation between Hsp27 serum levels and severity of coronary narrowings assessed by Gensini score was found (r = 0.21, p = 0.11).
Conclusions: Serum level of Hsp27 seems to be a potential marker of myocardial ischaemia caused by advanced 2- or 3-vessel CAD.

Abstract

Background: Heat shock protein (Hsp) 27 expression in cardiomyocytes increases in response to ischaemia. The extracellular release of Hsp27 from cardiomyocytes is proportional to its intracellular levels.
Aim: To assess the influence of significant coronary artery disease (CAD), which by definition results in chronic myocardial ischaemia, on blood serum levels of Hsp27.
Methods: Blood serum levels of Hsp27 in 62 patients with at least 50% lumen diameter narrowing in at least one main epicardial coronary artery on angiography and in 21 controls with normal coronaries were measured.
Results: Patients with CAD tended to have higher serum level of Hsp27 than controls [0.463 (0.158-0.809) vs. 0.184 (0.099-0.337) ng/ml, p = 0.084]. Serum Hsp27 level in patients with CAD affecting more than a single vessel was significantly increased [0.529 (0.192-1.004) ng/ml] compared with controls (p = 0.035) and with one artery narrowed [0.276 (0.087-0.549) ng/ml, p = 0.041]. No correlation between Hsp27 serum levels and severity of coronary narrowings assessed by Gensini score was found (r = 0.21, p = 0.11).
Conclusions: Serum level of Hsp27 seems to be a potential marker of myocardial ischaemia caused by advanced 2- or 3-vessel CAD.
Get Citation

Keywords

coronary artery disease; coronary atherosclerosis; coronary flow reserve

About this article
Title

Original article
Is Hsp27 a marker of myocardial ischaemia?

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 67, No 9 (2009)

Pages

947-952

Published online

2009-10-12

Bibliographic record

Kardiol Pol 2009;67(9):947-952.

Keywords

coronary artery disease
coronary atherosclerosis
coronary flow reserve

Authors

Grażyna Józefowicz-Okonkwo
Karina Wierzbowska-Drabik
Marek Kasielski
Ewa Trzos
Anna Gorąca
Jarosław Kasprzak
Maria Krzemińska-Pakuła

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl